# First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

> **NCT04360434** · PHASE1 · COMPLETED · sponsor: **Neurimmune AG** · enrollment: 46 (actual)

## Conditions studied

- Amyloid Transthyretin Cardiomyopathy

## Interventions

- **DRUG:** NI006
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04360434
- **Lead sponsor:** Neurimmune AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-10
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04360434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04360434, "First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04360434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*